Cystatin C Blood Test: When It Adds Useful Information Beyond Creatinine

Cystatin C is a protein produced continuously by virtually all nucleated cells in the body, and it's freely filtered by the kidneys without being significantly reabsorbed or secreted by the kidney tubules, similar in principle to creatinine. Because its production doesn't depend heavily on muscle mass the way creatinine's does, cystatin C blood levels are thought to more consistently reflect true filtration rate across people with different body compositions.

eGFR can be calculated using cystatin C alone (eGFRcys) or combined with creatinine (eGFRcr-cys), and current guidance specifically recommends the combined equation in situations where confirmation of a creatinine-based result is needed. If a creatinine-based eGFR and a cystatin C-based eGFR are broadly consistent with each other, this increases confidence in the result. If they disagree meaningfully, this discordance itself is informative and often prompts a closer look at factors like muscle mass, inflammation, or thyroid function that could be affecting one measure more than the other.

Cystatin C-based eGFR uses the same category framework as creatinine-based eGFR (G1 through G5), since both are attempting to estimate the same underlying physiological quantity — filtration rate. The specific clinical scenario where guidelines most clearly recommend cystatin C is confirmatory testing in adults with a creatinine-based eGFR of roughly 45 to 59 mL/min/1.73m² and no other marker of kidney damage (such as elevated uACR), since this intermediate range is exactly where reclassification based on a more muscle-mass-independent measure is most likely to change the overall risk picture.

While cystatin C is less affected by muscle mass than creatinine, it isn't immune to other confounders. Significant systemic inflammation, uncontrolled thyroid disease (both hyper- and hypothyroidism), and, to a lesser extent than with creatinine, body composition and smoking status have all been associated with changes in cystatin C independent of true kidney filtration.

A single cystatin C-based eGFR does not, by itself, establish chronic kidney disease — like creatinine-based eGFR, it requires persistence over time (generally three months or more) and, ideally, corroboration with albuminuria status before a diagnosis is made.

A common misunderstanding is assuming cystatin C is simply a 'better' test that should replace creatinine for everyone. Its main advantage is specific to situations where muscle mass is atypical or where a creatinine-based result is ambiguous; for most people with typical muscle mass and a clearly normal or clearly abnormal creatinine-based eGFR, cystatin C adds little additional information.

If your creatinine-based eGFR falls in the intermediate 45–59 mL/min/1.73m² range without other clear signs of kidney damage, asking whether cystatin C-based confirmatory testing is appropriate is a reasonable question for a clinician. If you have unusually high or low muscle mass — from bodybuilding, long-term illness, or limb loss — mentioning this is useful context when your eGFR result is being interpreted.

Cystatin C is not universally available and is not intended as first-line, routine testing for everyone; its value is concentrated in specific diagnostic-uncertainty situations rather than across the general population.

Read alongside the Elements84 guides to creatinine and eGFR and to urine albumin-to-creatinine ratio, since cystatin C is used to refine, not replace, the broader kidney-function picture those tests establish.